Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 19/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | CTSL | P07711 | 1/20 | 0.41 |
| ▸ | CTSK | P43235 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5517725 | 0.84 | CTSS (0.48) | CTSSCYP3A4CYP2C9 | |
| SCHEMBL5519481 | 0.84 | CTSS (0.48) | CTSSCYP3A4CYP2C9 | |
| SCHEMBL6048146 | 0.82 | CTSS (0.50) | CTSSCYP3A4CYP2C9 | |
| SCHEMBL3869248 | 0.80 | HDAC4 (0.39) | — | |
| SCHEMBL5800404 | 0.77 | CTSS (0.43) | CTSSCYP3A4CYP2C9CTSK | |
| SCHEMBL27663441 | 0.77 | CTSS (0.57) | CTSSCYP3A4CYP2C9 | |
| SCHEMBL3870014 | 0.76 | FAAH (0.40) | CTSSCYP3A4CYP2C9 | |
| SCHEMBL5519871 | 0.76 | FAAH (0.43) | CTSSCYP3A4CYP2C9 | |
| SCHEMBL5520458 | 0.76 | FAAH (0.43) | CTSSCYP3A4CYP2C9 | |
| SCHEMBL3877761 | 0.76 | CTSS (0.49) | CTSSCYP3A4CYP2C9CTSLCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7482448-B2 | Compounds and compositions as cathepsin inhibitors | AVENTIS PHARMACEUTICALS INC. (US) | 2009-01-27 | — | — | US | disclosed |
| US-20060189657-A1 | Novel compounds and compositions as cathepsin inhibitors | AVENTIS PHARMACEUTICALS INC. (US) | 2006-08-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060189657-A1 | Novel compounds and compositions as cathepsin inhibitors | CTSB, CTSS, CTSK | CTSS 2/4885CYP3A4 2062/4885CYP2C9 1881/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.